MX2021010631A - Modified rnai agents. - Google Patents
Modified rnai agents.Info
- Publication number
- MX2021010631A MX2021010631A MX2021010631A MX2021010631A MX2021010631A MX 2021010631 A MX2021010631 A MX 2021010631A MX 2021010631 A MX2021010631 A MX 2021010631A MX 2021010631 A MX2021010631 A MX 2021010631A MX 2021010631 A MX2021010631 A MX 2021010631A
- Authority
- MX
- Mexico
- Prior art keywords
- dsrna
- strand
- inhibiting
- expression
- rnai agents
- Prior art date
Links
- 108091030071 RNAI Proteins 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Abstract
One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene. The dsRNA duplex comprises one or more motifs of three identical modifications on three consecutive nucleotides in one or both strand, particularly at or near the cleavage site of the strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2021010631A MX2021010631A (en) | 2021-09-03 | 2021-09-03 | Modified rnai agents. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2021010631A MX2021010631A (en) | 2021-09-03 | 2021-09-03 | Modified rnai agents. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010631A true MX2021010631A (en) | 2023-03-06 |
Family
ID=89843925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010631A MX2021010631A (en) | 2021-09-03 | 2021-09-03 | Modified rnai agents. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX2021010631A (en) |
-
2021
- 2021-09-03 MX MX2021010631A patent/MX2021010631A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018012038A (en) | Modified rnai agents. | |
| MX2017002144A (en) | Modified double-stranded rna agents. | |
| MX2019005816A (en) | Modified rna agents with reduced off-target effect. | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| MX2021006745A (en) | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF. | |
| WO2014022739A3 (en) | Modified rnai agents | |
| MX2010009195A (en) | Ultra-small rnas as toll-like receptor-3 antagonists. | |
| MX2021012126A (en) | Compositions and methods for inhibiting gene expression in the central nervous system. | |
| MX354940B (en) | Functionally-modified oligonucleotides and subunits thereof. | |
| MX2023008478A (en) | 5'-cyclo-phosphonate modified nucleotides. | |
| BR112014011896A2 (en) | nasal agents, compositions and methods of use thereof for the treatment of transthyretin (ttr) -associated diseases | |
| TW201712023A (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| AR084319A1 (en) | MicroRNA INHIBITORS (miRNA OR miR) THAT INCLUDE BLOCKED NUCLEOTIDES | |
| WO2008154482A3 (en) | Sirna compositions and methods of use in treatment of ocular diseases | |
| AR107579A1 (en) | COMPOSITIONS AND METHODS TO DECREASE TAU EXPRESSION | |
| CY1123639T1 (en) | MONOCLON OLIGONUCLEOTIDES FOR USE IN THE MEDICAL THERAPEUTIC TREATMENT OF SKIN DISORDERS | |
| MX2020012652A (en) | Amphiregulin gene-specific double-stranded oligonucleotide and composition, for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same. | |
| MX2007011665A (en) | Influenza therapeutic. | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| BR112015024760A2 (en) | modified beta oligonucleotide for use in a method of preventing and / or treating an ophthalmic disease | |
| MX2021010631A (en) | Modified rnai agents. | |
| WO2005019410A3 (en) | Rnai agents for anti-sars coronavirus therapy | |
| AR123679A1 (en) | RNAi COMPOSITIONS AGAINST THE SNCA GENE AND METHODS OF USE THEREOF TO TREAT OR PREVENT NEURODEGENERATIVE DISEASES ASSOCIATED WITH SNCA | |
| BR112021024764A2 (en) | Antisense oligonucleotide capable of altering pre-mRNA splicing of dux4 | |
| MX2022005900A (en) | Il-34 antisense agents and methods of using same. |